Guidance and quality standards awaiting development | Guidance

Showing 111 to 120 of 410

Guidance and quality standards awaiting development
Title	Type
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]	Technology appraisal guidance
Edaravone for treating amyotrophic lateral sclerosis [TSID11869]	Technology appraisal guidance
Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide [TSID10046]	Technology appraisal guidance
Efzimfotase alfa for treating hypophosphatasia [ID6633]	Technology appraisal guidance
Elacestrant with everolimus for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment [ID6753]	Technology appraisal guidance
Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359]	Technology appraisal guidance
Elinzanetant for treating vasomotor symptoms caused by adjuvant endocrine treatment to prevent or treat hormone-receptor positive breast cancer [ID6544]	Technology appraisal guidance
Elranatamab for treating relapsed or refractory multiple myeloma after 2 treatments [ID6464]	Technology appraisal guidance
Elranatamab for treating relapsed or refractory multiple myeloma after treatments including anti-CD38 antibody and lenalidomide therapy [ID6591]	Technology appraisal guidance
Emactuzumab for treating localised or diffuse tenosynovial giant cell tumours when surgery is unsuitable [GID-TA12000]	Technology appraisal guidance